MedTrace Logo

Hypoxia Analysis in Head and/or Neck Cancer

NCT02414048 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-06-17

No results posted yet for this study

Summary

The primary objective is the prospective determination of disease-specific and overall survival in head and neck cancer patients who have undergone surgery, correlated to non-invasive methods of measuring tumour hypoxia.

The secondary objective is to define tumour hypoxia using non-invasive methodology.

Conditions

Interventions

DRUG

Pimonidazole

Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour

Sponsors & Collaborators

  • Marius Gustav Bredell

    lead OTHER

Principal Investigators

  • Marius Bredell · Department of Cranio-, Maxillofacial and Oral Surgery, University Hospital Zurich

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414048 on ClinicalTrials.gov